dementia

New monitoring technology is helping family caregivers manage the relentless task of looking out for older adults with cognitive decline. But it's not an option for everyone.

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

Scientists have created detailed maps of the brain area that controls movement in mice, monkeys and people. The maps could help explain human ailments like Alzheimer's and Lou Gehrig's disease.

The condition can be an early signal of Alzheimer’s but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.

Alzheimer's researchers are trying new treatment approaches, including trying to boost the immune system, remove toxic tangles of protein and stimulate brain waves with light and sound.

Weeks after the FDA approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.

The FDA approves new prescribing instructions for Aduhelm to address confusion over who should get the drug, saying it is appropriate for patients with early or mild Alzheimer’s.

Gov. Ron DeSantis, speaking at a Jacksonville assisted living facility, says the funding will help support Alzheimer’s research grants at institutions around the state.

This is the first new drug approved for Alzheimer's disease since 2003. It's the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease.

Researchers are looking to enroll 7,600 people for the study into whether computer-based cognitive training can prevent and even improve disorders such as dementia and Alzheimer’s disease.